MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

Q2 2025 Earnings Call Transcript August 12, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.32. Operator: Good morning, ladies and gentlemen, and ...

Altimmune ( ($ALT) ) has released its Q2 earnings. Here is a breakdown of the information Altimmune presented to its investors. Altimmune, Inc. is ...

National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise ...

Altimmune (NASDAQ:ALT) shares surge 8% post-promising Q2 results, driven by pemvidutide's success in metabolic and liver conditions. Read more here.

UC Davis Health researchers have discovered that a natural molecule made by gut bacteria can reverse liver damage and repair ...

Below are the transcripts from the Q2 earnings call. This transcript is brought to you by Benzinga APIs. For real-time access ...

Altimmune, Inc. ( NASDAQ: ALT) Q2 2025 Earnings Call August 12, 2025 8:30 AM ET Gregory L. Weaver - Chief Financial Officer Scott Harris - Corporate Participant Vipin K. Garg - President, CEO & ...